CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
Authors:
- Atsushi SugiyamaASAtsushi Sugiyama
- Naohiko TanabeNTNaohiko Tanabe
- Wataru KikushimaWKWataru Kikushima
- Atsuki KumeAKAtsuki Kume
- Hiroyuki IijimaHIHiroyuki Iijima
- 1 October 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Retina
- Vol. 37 (10) , 1866-1872
Abstract
Purpose: To investigate factors associated with visual improvement and retreatment 12 months after a combination therapy of intravitreal injection of ranibizumab or aflibercept followed by photodynamic therapy for polypoidal choroidal vasculopathy. Methods: Changes in the best-corrected visual acuity and the subfoveal thickness of the retina and choroid were studied in 56 consecutive eyes with polypoidal choroidal vasculopathy treated initially with a combination therapy of either intravitreal ranibizumab injection (n = 23) or intravitreal aflibercept injection (n = 33) followed by photodynamic therapy. Factors associated with visual improvement and retreatment were investigated. Results: Best-corrected visual acuity significantly improved with significant reduction in central macular thickness and subfoveal choroidal thickness at all points irrespective of treatment modalities (P < 0.001). Better best-corrected visual acuity and improvement of best-corrected visual acuity at 12 months were associated with baseline greater subfoveal choroidal thickness (P = 0.028 and P = 0.028) and baseline smaller greatest linear dimension (P = 0.0077 and P = 0.0077). Retreatment during 12-month follow-up was associated with baseline lesser subfoveal choroidal thickness (P = 0.036). Conclusion: Irrespective of treatment modalities, the visual outcome at 12 months is favorable in eyes with polypoidal choroidal vasculopathy treated by photodynamic therapy combined with intravitreal ranibizumab or aflibercept. Baseline greater subfoveal choroidal thickness was associated with a better visual outcome and with reduction in the need for retreatment.Keywords
This publication has 28 references indexed in Scilit:
- Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2013
- Association of Lesion Size and Visual Prognosis to Polypoidal Choroidal VasculopathyAmerican Journal of Ophthalmology, 2011
- Subfoveal Retinal and Choroidal Thickness After Verteporfin Photodynamic Therapy for Polypoidal Choroidal VasculopathyAmerican Journal of Ophthalmology, 2011
- Combined Photodynamic Therapy With Verteporfin and Intravitreal Bevacizumab for Polypoidal Choroidal VasculopathyAmerican Journal of Ophthalmology, 2010
- The multifunctional choroidProgress in Retinal and Eye Research, 2010
- Protective Effect of Intravitreal Bevacizumab and Sub-Tenon Triamcinolone Acetonide against Occlusion of Choriocapillaris Induced by Photodynamic TherapyOphthalmologica, 2010
- Polypoidal Choroidal Vasculopathy with Choroidal Vascular HyperpermeabilityAmerican Journal of Ophthalmology, 2006
- Expression of VEGF and PEDF in Choroidal Neovascular Membranes Following Verteporfin Photodynamic TherapyAmerican Journal of Ophthalmology, 2006
- INDOCYANINE GREEN VIDEOANGIOGRAPHY OF IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHYRetina, 1995
- IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV)Retina, 1990